Gold prices steady with focus on Ukraine-Russia, Jackson Hole
Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a $2.06 billion market cap biotech company, sold 10,000 ordinary shares on July 25, 2025, for $155,598. The shares were sold at prices ranging from $15.315 to $15.67, close to the current trading price of $15.41. According to InvestingPro analysis, the stock appears overvalued at current levels.
According to a Form 4 filing with the Securities and Exchange Commission, Weinhoff also exercised options to acquire 10,000 ordinary shares at an exercise price of $3.85, for a total value of $38,500. The company maintains strong financial health with a current ratio of 14.37, indicating ample liquidity to meet short-term obligations.
Following the sale, Weinhoff directly owns 122,279 ordinary shares of Centessa Pharmaceuticals. The sale was executed under a Rule 10b5-1 trading plan adopted on May 22, 2024. Get access to more exclusive insider trading insights and 6 additional ProTips with an InvestingPro subscription.
In other recent news, Centessa Pharmaceuticals has been the focus of analyst attention and executive changes. Truist Securities initiated coverage on Centessa Pharmaceuticals with a Buy rating and set a price target of $30.00, highlighting the potential of the company’s Orexin-2 receptor agonist, ORX750, which targets conditions like narcolepsy and idiopathic hypersomnia. Piper Sandler also maintained its Overweight rating on Centessa, with a price target of $38.00, following a discussion with a sleep medicine specialist about the ORX750 treatment’s potential. The firm expressed continued interest in Centessa, with key data from the Phase 2 CRYSTAL-1 study expected in 2025.
Additionally, Centessa Pharmaceuticals announced the appointment of Raphael Deferiere as the new Chief Accounting Officer, effective May 27, 2025. Deferiere, who has a significant background in accounting, previously worked as an Assurance Partner at Ernst & Young, LLP. These developments indicate a period of strategic focus for the company, with both executive appointments and analyst endorsements highlighting its ongoing initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.